USPH Competitors

Stocks . USA . 
Stock . US Physicalrapy
USPH Stock  USD 97.08  1.52  1.54%   
US Physicalrapy competes with Acadia Healthcare, Tenet Healthcare, HCA Holdings, DaVita HealthCare, and InnovAge Holding; as well as few others. The company conducts business under Health Care Providers & Services sector and is part of Health Care industry. Analyzing US Physicalrapy competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of US Physicalrapy to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out US Physicalrapy Correlation with its peers.
For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of US Physicalrapy competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
94.4397.0899.73
Details
Intrinsic
Valuation
LowRealHigh
86.6689.31106.79
Details
Naive
Forecast
LowNextHigh
94.5497.1999.85
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
77.7090.54103.39
Details

US Physicalrapy Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between US Physicalrapy and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of USPH and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of US Physicalrapy does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
SGRY
+ 0.9
HCA
SGRY
+ 0.83
INNV
AGL
+ 0.78
ACHC
SGRY
+ 0.78
PNTG
PNTG
+ 0.75
HCA
HCA
+ 0.74
ACHC
  
High negative correlations   
ENSG
- 0.44
DVA
INNV
- 0.4
DVA
DVA
- 0.16
THC
SGRY
- 0.05
DVA

Risk-Adjusted Indicators

There is a big difference between USPH Stock performing well and US Physicalrapy Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze US Physicalrapy's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ACHC  2.25 (1.02) 0.00 (5.78) 0.00 
 0.00 
 3.36 
(5.78)
 21.88 
THC  2.09 (0.28) 0.00 (0.18) 0.00 
 0.00 
 3.81 
(4.49)
 21.18 
HCA  1.19 (0.35) 0.00 (0.62) 0.00 
 0.00 
 2.06 
(2.82)
 11.25 
DVA  1.35  0.08  0.02  0.22  2.26 
(1.39)
 3.21 
(2.24)
 14.55 
INNV  2.19 (0.36) 0.00  1.28  0.00 
 0.00 
 4.23 
(4.81)
 11.60 
AGL  5.42 (1.09) 0.00 (0.23) 0.00 
 0.00 
 9.62 
(11.52)
 45.03 
EHAB  1.84 (0.26) 0.00 (0.09) 0.00 
 0.00 
 5.22 
(4.56)
 11.79 
ENSG  1.05  0.01  0.00  0.07  0.00 
 0.00 
 2.32 
(2.11)
 10.08 
PNTG  2.07 (0.03) 0.00  1.54  0.00 
 0.00 
 4.12 
(3.84)
 12.42 
SGRY  2.09 (0.57) 0.00 (0.42) 0.00 
 0.00 
 3.72 
(4.88)
 17.97 
All Fundamental Data

US Physicalrapy Competitive Analysis

The better you understand US Physicalrapy competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, US Physicalrapy's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across US Physicalrapy's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
USPH ACHC THC HCA DVA INNV AGL EHAB ENSG PNTG
 1.54 
 97.08 
USPH
 0.61 
 41.28 
Acadia
 2.51 
 141.98 
Tenet
 1.06 
 325.47 
HCA
 1.39 
 165.63 
DaVita
 0.63 
 4.80 
InnovAge
 2.93 
 2.11 
Agilon
 0.79 
 7.62 
Enhabit
 0.25 
 145.98 
Ensign
 1.01 
 31.39 
Pennant
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Slightly risky
Relatively risky
Somewhat reliable
Very steady
Very steady
Market Performance
(90 Days Performance)
Modest
Very Weak
Very Weak
Very Weak
Modest
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Below Average
Low
Low
Low
Low
Low
Above Average
Very Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Buy
Hold
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Hold
Strong Sell
Cautious Hold
Hold
Hold
Strong Sell
Cautious Hold
Hold
Strong Sell
Strong Sell
Current Ratio
1.43
1.17
1.4
1.38
1.41
2.29
2.65
1.41
1.28
1.0
Net Asset
997.24 M
5.36 B
28.31 B
56.21 B
16.89 B
547.66 M
1.74 B
1.43 B
4.18 B
539.69 M
Profit Margin
0.0357
0.0899
0.15
0.0852
0.0653
-0.0203
-0.0688
-0.11
0.0584
0.0324
EBITDA
74.37 M
189.11 M
3.39 B
12.72 B
2.35 B
1.15 M
(167.64 M)
(16.5 M)
353.24 M
30.64 M
Operating Margin
0.11
0.18
0.14
0.14
0.16
-0.0239
-0.091
0.039
0.0826
0.0598
Current Valuation
1.6 B
5.74 B
22.63 B
125.32 B
24.69 B
670.4 M
520.33 M
918.46 M
9.81 B
1.45 B
Price To Book
3.08
1.26
3.61
293.44
35.63
2.48
1.51
0.68
4.79
6.37
Retained Earnings
223.77 M
131.72 M
(192 M)
(1.35 B)
598.29 M
(68.31 M)
(1.33 B)
254.5 M
1.14 B
34.66 M
Current Asset
60.18 M
294.74 M
3.38 B
9.23 B
544.53 M
3.06 M
1.54 B
N/A
279.57 M
N/A
Five Year Return
1.01
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.39
N/A
Beta
1.39
1.33
2.15
1.69
0.89
0.39
0.6
1.38
0.95
2.02
Number Of Employees
3.9 K
17 K
78.81 K
220 K
70 K
2.35 K
1.12 K
10.8 K
35.3 K
5.79 K
Shares Outstanding
15.1 M
92.89 M
95.1 M
253.3 M
82.02 M
135.46 M
412.02 M
50.28 M
57.3 M
34.35 M
Cash Flow From Operations
81.98 M
462.34 M
2.37 B
9.43 B
2.06 B
(36.9 M)
(156.2 M)
48.4 M
376.67 M
33.09 M
Annual Yield
0.0181
N/A
N/A
0.008
N/A
N/A
N/A
N/A
0.0016
N/A
Total Debt
258.59 M
1.51 B
16.21 B
41.86 B
11.12 B
113.03 M
52.31 M
610.1 M
1.87 B
329.63 M
Return On Equity
0.0475
0.0976
0.6
0.12
0.45
-0.0603
-0.43
-0.17
0.15
0.14
Return On Asset
0.0424
0.0606
0.0699
0.12
0.0694
-0.0202
-0.0984
0.0177
0.0402
0.0383
Number Of Shares Shorted
682.02 K
6.55 M
2.08 M
2.97 M
3.9 M
303.26 K
30.39 M
1.22 M
2.21 M
775.66 K
Book Value Per Share
32.02
33.04
40.32
-8.57
4.68
1.93
1.4
11.3
30.71
5.54
Current Liabilities
19.01 M
290.2 M
2.55 B
5.52 B
292.6 M
4.22 M
2.49 B
N/A
179.87 M
N/A
Total Asset
997.24 M
5.36 B
28.31 B
56.21 B
16.89 B
547.66 M
1.74 B
1.43 B
4.18 B
539.69 M
Debt To Equity
0.57
0.58
3.3
N/A
5.68
0.24
0.051
0.72
1.25
2.66
Short Ratio
5.95
3.59
1.48
1.84
4.32
10.01
6.09
3.2
4.86
3.32
Target Price
107.4
60.17
182.46
404.19
156.9
7.0
3.63
8.65
169.5
38.25
Last Dividend Paid
1.75
N/A
N/A
2.58
N/A
N/A
N/A
N/A
0.24
N/A
Shares Owned By Institutions
98.42
97.03
96.72
63.59
50.25
11.9
98.22
97.38
96.55
78.47
Market Capitalization
1.47 B
3.83 B
13.85 B
82.44 B
13.59 B
650.18 M
869.36 M
383.16 M
8.36 B
1.08 B
Price To Earning
34.35
25.67
11.95
13.57
11.43
33.64
23.14
6.49
29.5
34.12
Price To Earnings To Growth
3.91
1.32
0.68
1.06
1.27
N/A
0.19
-1.7
1.58
2.17
Price To Sales
2.29
1.23
0.66
1.18
1.07
0.83
0.16
0.37
2.04
1.65
Net Income
37.22 M
(21.67 M)
611 M
5.24 B
691.53 M
(23.22 M)
(262.8 M)
(80.5 M)
209.85 M
13.91 M
Earnings Per Share
0.88
3.07
30.78
22.03
9.16
-0.12
-0.76
-2.33
4.13
0.68
Shares Owned By Insiders
1.58
2.97
1.16
28.42
48.53
85.03
1.79
2.62
3.29
3.94
Revenue
604.8 M
2.93 B
20.55 B
64.97 B
12.14 B
763.86 M
4.32 B
1.05 B
3.73 B
544.89 M
Working Capital
131.19 M
(289.78 M)
2.41 B
2.27 B
495.69 M
34.54 M
502.92 M
72.4 M
312.18 M
8.53 M
Cash And Equivalents
48.57 M
128.37 M
858 M
908 M
244.09 M
184.43 M
497.07 M
50.2 M
321.1 M
3.2 M
Cash Per Share
3.73
1.41
11.19
3.97
3.98
1.36
2.32
1.01
5.79
0.11
Gross Profit
112.02 M
1.12 B
7.05 B
23.18 B
3.4 B
475.82 M
112.29 M
545.5 M
534.92 M
103.15 M
Day Typical Price
97.66
41.28
143.76
327.46
166.91
4.85
2.11
7.69
145.99
31.41
Accumulation Distribution
0.0248
0.0161
0.038
0.0213
0.0233
0.0559
0.0685
0.048
0.0113
0.0329
Market Facilitation Index
2.46
0.67
5.61
7.06
3.95
0.28
0.15
0.38
1.66
1.05
Daily Balance Of Power
(0.62)
0.3731
(0.65)
(0.49)
(0.59)
0.1071
0.4
0.1579
(0.22)
(0.30)
Period Momentum Indicator
(1.52)
0.25
(3.66)
(3.48)
(2.33)
0.03
0.06
0.06
(0.36)
(0.32)
Rate Of Daily Change
0.98
1.01
0.97
0.99
0.99
1.01
1.03
1.01
1.0
0.99
Day Median Price
97.95
41.29
144.64
328.46
167.55
4.87
2.12
7.73
146.0
31.42
Price Action Indicator
(1.63)
0.12
(4.50)
(4.73)
(3.08)
(0.06)
0.025
(0.08)
(0.20)
(0.19)
Relative Strength Index
63.25
31.23
40.96
32.1
58.88
36.37
42.51
51.37
46.09
46.26
Coefficient Of Variation
1114.38
(391.24)
(2,050)
(619.23)
1235.85
(716.88)
(1,071)
(2,597)
(13,824)
(11,680)
Mean Deviation
1.35
2.25
2.09
1.19
1.35
2.19
5.42
1.84
1.05
2.07
Jensen Alpha
0.2009
(1.02)
(0.28)
(0.35)
0.0756
(0.36)
(1.09)
(0.26)
0.0137
(0.03)
Total Risk Alpha
(0.17)
(1.58)
(0.65)
(0.56)
(0.15)
(0.82)
(1.89)
(0.51)
(0.25)
(0.42)
Sortino Ratio
0.0757
N/A
N/A
N/A
0.0166
N/A
N/A
N/A
N/A
N/A
Downside Variance
2.14
N/A
N/A
N/A
6.31
N/A
N/A
N/A
N/A
N/A
Standard Deviation
2.63
3.86
3.21
1.77
2.06
2.79
7.71
2.62
1.49
2.57
Kurtosis
30.69
9.61
11.39
8.04
11.69
(0.16)
4.83
1.19
5.96
0.239
Potential Upside
3.06
3.36
3.81
2.06
3.21
4.23
9.62
5.22
2.32
4.12
Treynor Ratio
1.03
(5.78)
(0.18)
(0.62)
0.2225
1.28
(0.23)
(0.09)
0.0696
1.54
Maximum Drawdown
20.31
21.88
21.18
11.25
14.55
11.6
45.03
11.79
10.08
12.42
Variance
6.93
14.87
10.33
3.13
4.26
7.8
59.42
6.88
2.22
6.59
Market Risk Adjusted Performance
1.04
(5.77)
(0.17)
(0.61)
0.2325
1.29
(0.22)
(0.08)
0.0796
1.55
Risk Adjusted Performance
0.0759
(0.19)
(0.03)
(0.12)
0.0683
(0.1)
(0.06)
(0.02)
(0.0007)
5.0E-4
Skewness
4.69
(2.69)
2.14
(2.06)
(2.24)
0.1089
(0.82)
0.1553
(1.02)
(0.37)
Semi Deviation
1.26
N/A
N/A
N/A
2.26
N/A
N/A
N/A
N/A
N/A
Information Ratio
0.0421
(0.29)
(0.09)
(0.23)
0.0202
(0.18)
(0.11)
(0.09)
(0.09)
(0.06)
Value At Risk
(2.56)
(5.78)
(4.49)
(2.82)
(2.24)
(4.81)
(11.52)
(4.56)
(2.11)
(3.84)
Expected Short fall
(1.67)
N/A
N/A
N/A
(1.39)
N/A
N/A
N/A
N/A
N/A
Downside Deviation
1.46
N/A
N/A
N/A
2.51
N/A
N/A
N/A
N/A
N/A
Semi Variance
1.59
N/A
N/A
N/A
5.12
N/A
N/A
N/A
N/A
N/A

US Physicalrapy Competition Performance Charts

Five steps to successful analysis of US Physicalrapy Competition

US Physicalrapy's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by US Physicalrapy in relation to its competition. US Physicalrapy's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of US Physicalrapy in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact US Physicalrapy's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to US Physicalrapy, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your US Physicalrapy position

In addition to having US Physicalrapy in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Industrials ETFs Thematic Idea Now

Industrials ETFs
Industrials ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Industrials ETFs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Industrials ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether US Physicalrapy offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of US Physicalrapy's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Us Physicalrapy Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Us Physicalrapy Stock:
How To Invest In USPH
Details
Is USPH Stock a good investment?
Details
What is US Physicalrapy's Net Worth?
Details
Largest Healthcare Companies
View
Largest Medical Care Facilities Companies
View
Check out US Physicalrapy Correlation with its peers.
For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Healthcare space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of US Physicalrapy. If investors know USPH will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about US Physicalrapy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of US Physicalrapy is measured differently than its book value, which is the value of USPH that is recorded on the company's balance sheet. Investors also form their own opinion of US Physicalrapy's value that differs from its market value or its book value, called intrinsic value, which is US Physicalrapy's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because US Physicalrapy's market value can be influenced by many factors that don't directly affect US Physicalrapy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between US Physicalrapy's value and its price as these two are different measures arrived at by different means. Investors typically determine if US Physicalrapy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, US Physicalrapy's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY